19Feb 2024
Fusion Pharmaceuticals Obtains Exclusive License for PSMA-Targeted Radiotherapy

Fusion Pharmaceuticals Obtains Exclusive License for PSMA-Targeted Radiotherapy

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) has secured an exclusive worldwide license agreement granting rights to develop and commercialize 225Ac-PSMA I&T (FPI-2265) for treating PSMA-expressing cancers. The agreement also settles a dispute related to an inter partes review of a U.S. patent. With further optimism about advancing FPI-2265, highlighting Fusion's expertise and operational capabilities. Anticipated milestones in 2024 include data from the TATCIST study in April and the initiation of a Phase 2/3 registrational study in the second quarter, following alignment with the FDA on the Phase 2/3 protocol.

  • #family health

Like

Save

Share